Evaluation of Perospirone (SM-9018), a Novel Serotonin-2 and Dopamine-2 Receptor Antagonist, and Other Antipsychotics in the Conditioned Fear Stress-Induced Freezing Behavior Model in Rats

スポンサーリンク

概要

• 論文の詳細を見る

• We studied the effects of perospirone (SM-9018), a novel serotonin-2 (5-HT<SUB>2</SUB>) and dopamine-2 (D<SUB>2</SUB>) receptor antagonist (SDA), on conditioned fear stress (CFS)-induced freezing behavior in rats and compared its actions with those of other antipsychotics. Exposure of rats to the environment previously paired with foot shock induced marked freezing behavior, which was reduced by the anxiolytic diazepam (0.1 minus; 3 mg/kg, p.o.) or antidepressants, desipramine and imipramine (10 minus; 100 mg/kg, p.o.). Perospirone at 0.3 minus; 3 mg/kg, p.o. significantly attenuated the CFS-induced freezing behavior in a dose-dependent manner, while the effect was reduced at the higher dose of 6 mg/kg. Other SDA-type antipsychotics, clozapine (1 minus 30mg/kg, p.o.) and risperidone (0.03 minus; 1 mg/kg, p.o.), and selective 5-HT<SUB>2</SUB> antagonists, ritanserin (0.1 minus; 1 mg/kg, p.o.) and ketanserin (0.3 minus; 1 mg/kg, p.o.), all reduced the freezing behavior with U-shaped dose-response curves. However, neither conventional antipsychotic, haloperidol (0.1 minus; 3 mg/kg, p.o.), chlorpromazine (3 minus; 100 mg/kg, p.o.), thioridazine (3 minus; 100 mg/kg, p.o.), mosapramine (3 minus; 100 mg/kg, p.o.) nor tiapride (30 minus; 1000 mg/kg, p.o.) reduced the CFS-induced freezing behavior. In addition, subacute treatment of rats with perospirone (1 minus; 10 mg/kg/day) or imipramine (30 mg/kg/day) for 2 weeks prevented the induction of the freezing behavior by CFS. These findings suggest that SDA-type antipsychotics including perospirone are effective for the treatment of mood disturbances such as anxiety and depressive mood associated with schizophrenia and have a broader efficacy profile as compared with the conventional antipsychotics.

• 社団法人 日本薬理学会の論文

著者

• Ohno Yukihiro

  Discovery Research Laboratories I Resarch Division Sumitomo Pharmaceuticals Co. Ltd.

• Ishida-Tokuda Kumiko

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Ohno Yukihiro

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Sakamoto Hideki

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Ishibashi Tadashi

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Wakabayashi Junko

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Tojima Rie

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Morita Tomoko

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Nakamura Mitsutaka

  Research Center, Sumitomo Pharmaceuticals Co., Ltd.

• Tojima Rie

  <I>Research Center, Sumitomo Pharmaceuticals Co., Ltd.</I>

• Ishida-Tokuda Kumiko

  <I>Research Center, Sumitomo Pharmaceuticals Co., Ltd.</I>

• Ohno Yukihiro

  <I>Research Center, Sumitomo Pharmaceuticals Co., Ltd.</I>

• Sakamoto Hideki

  <I>Research Center, Sumitomo Pharmaceuticals Co., Ltd.</I>

• Wakabayashi Junko

  <I>Research Center, Sumitomo Pharmaceuticals Co., Ltd.</I>

関連論文

• 7-Hydroxy-N,N'-di-n-propyl-2-aminotetraline, a Preferential Dopamine D_3 Agonist, Induces c-fos mRNA Expression in the Rat Cerebellum
• Effects of the Novel Tricyclic Quinoxalinedione Derivatives, SM-18400 and Its Analogs, on N-Methyl-D-aspartate (NMDA) Receptor-Mediated Synaptic Transmission in the Isolated Neonatal Rat Spinal Cord In Vitro
• (2R-trans)-2-Butyl-5-heptylpyrrolidine as a Potent Sigma Receptor Ligand Produced by Streptomyces longispororuber
• Evaluation of Perospirone (SM-9018), a Novel Serotonin-2 and Dopamine-2 Receptor Antagonist, and Other Antipsychotics in the Conditioned Fear Stress-Induced Freezing Behavior Model in Rats

スポンサーリンク